Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,277 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure.
de Bortoli N, Martinucci I, Savarino E, Franchi R, Bertani L, Russo S, Ceccarelli L, Costa F, Bellini M, Blandizzi C, Savarino V, Marchi S. de Bortoli N, et al. Among authors: costa f. Dis Esophagus. 2016 Jan;29(1):3-9. doi: 10.1111/dote.12284. Epub 2014 Sep 12. Dis Esophagus. 2016. PMID: 25212408
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.
Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, Bossa F, Maconi G, DʼIncà R, Lionetti P, Cantoro L, Fries W, Annunziata ML, Costa F, Terpin MM, Biancone L, Cortelezzi CC, Amato A, Ardizzone S, Danese S, Guidi L, Rizzuto G, Massella A, Andriulli A, Massari A, Lorenzon G, Ghione S, Kohn A, Ventra A, Annese V; PROSIT-BIO Cohort. Fiorino G, et al. Among authors: costa f. Inflamm Bowel Dis. 2017 Feb;23(2):233-243. doi: 10.1097/MIB.0000000000000995. Inflamm Bowel Dis. 2017. PMID: 28092307
Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.
Guidi L, Pugliese D, Panici Tonucci T, Berrino A, Tolusso B, Basile M, Cantoro L, Balestrieri P, Civitelli F, Bertani L, Marzo M, Felice C, Gremese E, Costa F, Viola F, Cicala M, Kohn A, Gasbarrini A, Rapaccini GL, Ruggeri M, Armuzzi A. Guidi L, et al. Among authors: costa f. J Crohns Colitis. 2018 Aug 29;12(9):1079-1088. doi: 10.1093/ecco-jcc/jjy076. J Crohns Colitis. 2018. PMID: 29860436
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy.
Armuzzi A, Fiorino G, Variola A, Manetti N, Fries W, Orlando A, Maconi G, Bossa F, Cappello M, Biancone L, Cantoro L, Costa F, D'Incà R, Lionetti P, Principi M, Castiglione F, Annunziata ML, Di Sabatino A, Di Girolamo M, Terpin MM, Cortelezzi CC, Saibeni S, Amato A, Ardizzone S, Guidi L, Danese S, Massella A, Ventra A, Rizzuto G, Massari A, Perri F, Annese V; PROSIT Investigators. Armuzzi A, et al. Among authors: costa f. Inflamm Bowel Dis. 2019 Feb 21;25(3):568-579. doi: 10.1093/ibd/izy264. Inflamm Bowel Dis. 2019. PMID: 30137352
Management of ulcerative colitis in a real-life setting: An Italian multicenter, prospective, observational AIGO study.
Scribano ML, Papi C, Costa F, Bortoli A, Bortoluzzi F, Buscarini E, Cappello M, Caserta L, Cortelezzi C, Ferronato A, Manguso F, Mazzuoli S, Orzes N, Kohn A; AIGO IBD Study Group. Scribano ML, et al. Among authors: costa f. Dig Liver Dis. 2019 Mar;51(3):346-351. doi: 10.1016/j.dld.2018.08.006. Epub 2018 Aug 16. Dig Liver Dis. 2019. PMID: 30195815
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn's disease: pharmacological and clinical implications.
Savarino E, Bertani L, Ceccarelli L, Bodini G, Zingone F, Buda A, Facchin S, Lorenzon G, Marchi S, Marabotto E, De Bortoli N, Savarino V, Costa F, Blandizzi C. Savarino E, et al. Among authors: costa f. Expert Opin Biol Ther. 2019 Feb;19(2):79-88. doi: 10.1080/14712598.2019.1561852. Epub 2019 Jan 2. Expert Opin Biol Ther. 2019. PMID: 30574820 Review.
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
Fiorino G, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, Fantini MC, Orlando A, Papi C, Annese V, Danese S, Vecchi M, Rizzello F, Armuzzi A; National patients’ association representatives. Fiorino G, et al. Dig Liver Dis. 2019 May;51(5):632-639. doi: 10.1016/j.dld.2019.02.004. Epub 2019 Feb 19. Dig Liver Dis. 2019. PMID: 30872085 Review.
4,277 results